Intracerebral Hemorrhage (ICH)NCT07100132
Research on the Clinical Value of Cranial CT and CTA for Cerebral Hemorrhage Patients
An observational study of Intracerebral Hemorrhage (ICH), run by The Affiliated Hospital Of Guizhou Medical University.
Trial summary
The objective of this observational study is to investigate the predictive value of various imaging signs in patients with intracerebral hemorrhage, thereby providing a reference for clinical diagnosis and treatment. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Intracerebral Hemorrhage (ICH)
- How many people
- 300 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2025to 1 Jun 2027
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients with cerebral hemorrhage treated at the Affiliated Hospital of Guizhou Medical University
Who may be able to join
- Patients who were confirmed to have cerebral hemorrhage through head CT imaging examination upon admission; (2) Those who completed head CT and CTA within 8 hours of onset and had a follow-up CT within 24 hours of admission; (3) With complete clinical data.
Who cannot join
- Patients who cannot complete CT and CTA within the prescribed time; (2) Patients with secondary cerebral hemorrhage due to cerebral vascular malformations, brain tumors, brain trauma, cerebral aneurysms, etc.; (3) Patients who have been taking oral anticoagulants for a long time or have blood system diseases; (4) Primary intraventricular hemorrhage.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Research on the Clinical Value of Cranial CT and CTA in Patients With Cerebral Hemorrhage
The objective of this observational study is to investigate the predictive value of various imaging signs in patients with intracerebral hemorrhage, thereby providing a reference for clinical diagnosis and treatment. The primary aim is to evaluate the association between specific imaging signs and both hematoma expansion and poor outcomes in these patients.
- Conditions
- Intracerebral Hemorrhage (ICH)
- Medical subject headings
- Cerebral Hemorrhage
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Based on the patients' neurological functional outcomes, they were categorized into a good prognosis | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Randomized 180-day mRS score of 0-3 (%)
Measured: From the end of the six-month period after discharge.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2025
- Study start1 Oct 2025 (estimated)
- Primary completion1 Jan 2027 (estimated)
- Study completion1 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intracerebral Hemorrhage (ICH)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- The Affiliated Hospital Of Guizhou Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07100132
- Sponsor's protocol ID
- GE2023JZ-01
- Status last verified
- Jul 2025
- First submitted
- 27 Jul 2025
- Last updated
- 3 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Research on the Clinical Value of Cranial CT and CTA in Patients With Cerebral Hemorrhage
- ClinicalTrials.gov ID
- NCT07100132
- Acronym / sponsor ID
- GE2023JZ-01
- Conditions
- Intracerebral Hemorrhage (ICH)
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- The Affiliated Hospital Of Guizhou Medical UniversityUniversity, hospital or other
- Study start
- 1 Oct 2025 (estimated)
- Primary completion
- 1 Jan 2027 (estimated)
- Study completion
- 1 Jun 2027 (estimated)
- First posted
- 3 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this observational study is to investigate the predictive value of various imaging signs in patients with intracerebral hemorrhage, thereby providing a reference for clinical diagnosis and treatment. The primary aim is to evaluate the association between specific imaging signs and both hematoma expansion and poor outcomes in these patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 6 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Based on the patients' neurological functional outcomes, they were categorized into a good prognosis | – | – |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients with cerebral hemorrhage treated at the Affiliated Hospital of Guizhou Medical University
Key inclusion criteria (1 listed)
- Patients who were confirmed to have cerebral hemorrhage through head CT imaging examination upon admission; (2) Those who completed head CT and CTA within 8 hours of onset and had a follow-up CT within 24 hours of admission; (3) With complete clinical data.
Key exclusion criteria (1 listed)
- Patients who cannot complete CT and CTA within the prescribed time; (2) Patients with secondary cerebral hemorrhage due to cerebral vascular malformations, brain tumors, brain trauma, cerebral aneurysms, etc.; (3) Patients who have been taking oral anticoagulants for a long time or have blood system diseases; (4) Primary intraventricular hemorrhage.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Randomized 180-day mRS score of 0-3 (%)
Time frame: From the end of the six-month period after discharge.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2025.
- Individual participant dataSharing planned: Yes
Related trials for Intracerebral Hemorrhage (ICH)
RecruitingObservational study
Sleep to Predict Recovery In Unconscious Patients With Acute Brain Injury
Traumatic Brain Injury (TBI) Patients, Intracerebral Hemorrhage (ICH)
Recruiting
TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage
Intracerebral Hemorrhage
Not yet recruiting
REmifentanil And Dexmedetomidine for EarlY Intensive Blood Pressure Lowering in ICH.
Intracerebral Hemorrhage
RecruitingObservational study
The Erlanger Stroke Registry (ESPro) is the Only Ongoing Prospective Population-based Stroke Registry in Germany, Started in 1994. ESPro Includes All Hospitalized and Non-hospitalized Patients With Stroke in the Community of Erlangen (120.000 Inhabitants), With a Long-life Follow-up.
Intracerebral Haemorrhage (ICH), Cerebral Infarction
Recruiting
Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation
Basal Ganglia Intracerebral Hemorrhage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Intracerebral Hemorrhage (ICH), run by The Affiliated Hospital Of Guizhou Medical University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Qian Wu (18586876127, 596914581@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Randomized 180-day mRS score of 0-3 (%) (time frame: From the end of the six-month period after discharge.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2025.